Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 10/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3441344 | 0.88 | PTGER4 (0.36) | PTGER4HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL3440844 | 0.87 | TGFBR1 (0.36) | HDAC1HDAC8HDAC6NPC1MAPT | |
| SCHEMBL3441342 | 0.86 | PTGER4 (0.35) | PTGER4HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL3440949 | 0.84 | HDAC1 (0.38) | PTGER4HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL3440969 | 0.83 | TGFBR1 (0.35) | PTGER4HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL3610657 | 0.83 | PTGER4 (0.37) | PTGER4HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL3441307 | 0.82 | HDAC1 (0.36) | PTGER4HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL3440966 | 0.81 | TRPM8 (0.35) | PTGER4HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL3441308 | 0.80 | BRD4 (0.36) | PTGER4HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL3603333 | 0.80 | BRD4 (0.39) | PTGER4HDAC1HDAC8HDAC6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286129-A1 | NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-11 | — | — | US | claimed |
| US-8232272-B2 | Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20100286129-A1 | NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286129-A1 | NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | FBP1, ALDOA, GCK | PTGER4 2701/4885HDAC1 243/4885HDAC8 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.